Author

Ewa Gatlik

Institution: Novartis (Switzerland)

Observed institutions: Novartis (Switzerland), Novartis Institutes for BioMedical Research

ORCID: 0000-0002-1258-2840

Observed ORCID: 0000-0002-1258-2840

OpenAlex ID: A5014285131

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

2022 · Ildiko Madurka, Alexander Vishnevsky, et al. · Infection · 88

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

2024 · Ewa Gatlik, Beata Mehes, et al. · Clinical and Translational Science · 68

Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug

2017 · Handan He, Phi Tran, et al. · Drug Metabolism and Disposition · 45

Plasma Protein Binding of Highly Bound Drugs Determined With Equilibrium Gel Filtration of Nonradiolabeled Compounds and LC-MS/MS Detection

2018 · John Isbell, Ding Yuan, et al. · Journal of Pharmaceutical Sciences · 25

Equilibrium Gel Filtration to Measure Plasma Protein Binding of Very Highly Bound Drugs

2013 · H. Markus Weiss, Ewa Gatlik · Journal of Pharmaceutical Sciences · 16

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

2022 · Diane M. Thiboutot, Noah Craft, et al. · Journal of Dermatological Treatment · 13

Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients

2010 · John M. Kovarik, Peter Neuhaus, et al. · Transplant International · 12

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

2024 · Guillermo Garcia-Manero, Yasmin Abaza, et al. · Blood · 10

Works count: 9

Citation count: 277

H-index: 8

I10-index: 8